Like many other cancer risk factors, a person's risk of getting cancer due to the use of hormone replacement therapy increases the longer they use it. The researchers conducted a large scale analysis that included data from more than 459,000 women under the age of 55 from North America, Europe, Asia and Australia. Women who used E-HT had a 14% reduction in the incidence of breast cancer compared to those who never used hormone therapy. It should be noted that this protective effect was more pronounced in women who started using E-HT at a younger age or who used it for a longer time. In contrast, women who used EP-HT experienced a 10% higher rate of breast cancer compared to those who didn't use it, and an 18% higher rate among women who used EP-HT for more than two years compared to those who never used the therapy.
The risk increases the longer you take it and the older you are. It falls back after you stop taking it. According to studies from the Women's Health Initiative and other research, in women without a history of breast cancer, estrogen-only systemic hormone replacement therapy is not linked to an increased risk of cancer From mom. In certain groups of women, such as those with no family history of breast cancer or benign breast disease, estrogen-only systemic HRT appears to reduce the risk of breast cancer.
While some chemotherapy and hormonal therapies used to treat breast cancer save lives, they can cause temporary or permanent menopause. Here's what's important to know about systemic hormone therapy (most often taken in pill form) and the risk of breast cancer. Like many other cancer risk factors, a person's risk of getting cancer from using hormone replacement therapy increases the longer they use it. Examples of hormone therapy used in breast cancer include tamoxifen and aromatase inhibitors, such as anastrozole, letrozole, or exemestane.
There isn't much data on the use of hormone replacement therapy in women who have or have had other types of breast cancer, such as triple-negative or ER-negative breast cancer. In these cases, systemic hormone replacement therapy to treat menopausal symptoms may not be an option because of the increased risk of recurrence. However, the use of combination hormone therapy in the short term (less than five years) was not associated with an increase of risk. Certainly, more research is needed to better understand the biological factors behind menopausal symptoms and how to improve them without using HRT in women with a history of breast cancer.
As a result, the North American Menopause Society revised its guidelines; HRT was recommended for women under 60 or within 10 years of menopause, especially if they were at greater risk of bone loss or fractures. Hormone therapy can be used to treat some types of cancer, such as certain types of breast cancer, that rely on hormones to spread. Joyce Slingerland is interested in how obesity and postmenopausal estrogens increase the risk and promote the progression of estrogen-receptor breast cancer. (ER) positive.
Increasingly, researchers are discovering that younger menopausal women with no history of breast cancer can experience significant improvements in quality of life by alleviating their menopause-related symptoms through hormone replacement therapy. Transgender men and non-binary people assigned to female sex at birth (AFAB) who take testosterone as a form of gender-affirming hormone therapy have a lower risk of breast cancer than cisgender or transgender women, but a higher risk than cisgender men. Today, new findings and updated research on hormone therapy and breast cancer risk provide women with more knowledge and empower them to make better and more informed decisions about their health together with their doctors. The results of the 20-year follow-up of the WHI study published this year revealed that the risk of breast cancer increased with long-term use of combined HRT, but the absolute risk (the likelihood of something happening) was low compared to placebo, and women aged 50 to 59 had a lower risk than women aged 60 and over.
